Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 61.3%

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 212,702 shares, a decline of 61.3% from the February 12th total of 549,047 shares. Based on an average daily trading volume, of 435,988 shares, the short-interest ratio is currently 0.5 days. Approximately 0.7% of the company’s stock are short sold. Approximately 0.7% of the company’s stock are short sold. Based on an average daily trading volume, of 435,988 shares, the short-interest ratio is currently 0.5 days.

Hedge Funds Weigh In On VYNE Therapeutics

Several large investors have recently modified their holdings of VYNE. Velan Capital Investment Management LP acquired a new position in VYNE Therapeutics in the second quarter worth about $50,000. XTX Topco Ltd acquired a new stake in VYNE Therapeutics during the fourth quarter valued at approximately $46,000. Boothbay Fund Management LLC acquired a new stake in VYNE Therapeutics during the second quarter valued at approximately $176,000. TFG Asset Management GP Ltd bought a new position in VYNE Therapeutics during the 2nd quarter worth approximately $190,000. Finally, Jane Street Group LLC bought a new position in VYNE Therapeutics during the 2nd quarter worth approximately $206,000. Institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Trading Down 0.3%

Shares of NASDAQ:VYNE opened at $0.60 on Thursday. The firm has a market cap of $19.99 million, a PE ratio of -0.77 and a beta of 2.00. The company has a fifty day simple moving average of $0.58 and a 200 day simple moving average of $0.45. VYNE Therapeutics has a 12-month low of $0.28 and a 12-month high of $1.99.

Analyst Upgrades and Downgrades

VYNE has been the subject of a number of analyst reports. Wall Street Zen raised shares of VYNE Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, January 21st. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $4.50.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.